


Express Mail Label No.: EV942367342US
Date of Deposit: June 21, 2007

06-25-09
1/14
Attorney Docket No: 24852-501 CIP5 NATL



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bacopoulos *et al.* CONF. NO.: 5498
SERIAL NO.: 10/567,952 EXAMINER: James D. Anderson
FILED: February 10, 2006 ART UNIT: 1614
FOR: METHODS OF TREATING CANCER WITH HDAC INHIBITORS

MAIL STOP AMENDMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited Reference B18; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24852-501 CIP5 NATL. Please address all correspondence to Customer No. 35437. A duplicate copy of this Transmittal Letter is enclosed herewith.

Respectfully submitted,

Dated: June 21, 2007

Michelle A. Iwamoto

Ivor Elrifi, Reg. No. 39,529

Michelle A. Iwamoto, Reg. No. 55,296

Attorneys for Applicants


c/o MINTZ, LEVIN, COHN, FERRIS, *et al.*

666 Third Avenue, 24th Floor

New York, New York 10017

Phone: (212) 935-3000

Fax: (212) 983-3115



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:	Bacopoulos <i>et al.</i>	CONF. NO.::	5498
SERIAL NO.:	10/567,952	EXAMINER:	James D. Anderson
FILED:	February 10, 2006	ART UNIT:	1614
FOR:	METHODS OF TREATING CANCER WITH HDAC INHIBITORS		

MAIL STOP AMENDMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the document listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, a copy of which is submitted herewith.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants: Bacopoulos et al.

U.S.S.N.: 10/567,952

Express Mail Label No.: EV942367342US

Date of Deposit: June 21, 2007

Attorney Docket No: 24852-501 CIP5 NATL

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **24852-501 CIP5 NATL**, Customer No. **35437**.

Respectfully submitted,

Dated: June 21, 2007

Michelle A Iwamoto

Ivor Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS, et al.
666 Third Avenue, 24th Floor
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115



Please type a plus sign (+) in this box +

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number 10/567,952
		Filing Date February 10, 2006
		First Named Inventor Bacopoulos
		Group Art Unit / Conf. No.: 1614 / 5498
		Examiner Name James D. Anderson
		Attorney Docket Number 24852-501 CIP5 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	English Yes No
	B18	WO 05/023179	Aton Pharma, Inc.; Sloan-Kettering Institute for Cancer Research		March 17, 2005	X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.